Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.77 |
| ▸ | NT5E | P21589 | 9/20 | 0.68 |
| ▸ | CD99 | P14209 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17752044 | 0.89 | ADORA2A (0.60) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL24195754 | 0.89 | NT5E (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL12746252 | 0.89 | PDE2A (0.82) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL14123296 | 0.89 | PDE2A (0.82) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10024078 | 0.89 | PDE2A (0.82) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10026366 | 0.89 | PDE2A (0.82) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Clofarabine SCHEMBL12139443 | 0.87 | PDE2A (1.00) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Clofarabine SCHEMBL1467619 | 0.87 | PDE2A (1.00) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Clofarabine SCHEMBL10026375 | 0.87 | PDE2A (1.00) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| Clofarabine SCHEMBL5975001 | 0.87 | PDE2A (1.00) | PDE2AADORA3ADORA2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137685-A1 | NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES | PATEL HASMUKH B (US) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137685-A1 | NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES | PNP, NTPCR, SLC29A1 | PDE2A 2541/4885ADORA3 131/4885ADORA2A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.